Patents Assigned to Merck
  • Publication number: 20250250486
    Abstract: Liquid-crystalline (LC) media having positive dielectric anisotropy and liquid-crystal displays (LCDs) containing these media, especially displays addressed by an active matrix and in particular energy efficient LC displays of the TN, PS-TN, STN, TN-TFT, OCB, IPS, PS-IPS, FFS, HB-FFS, XB-FFS, PS-FFS, SA-HB-FFS, SA-XB-FFS, polymer stabilised SA-HB-FFS, polymer stabilised SA-XB-FFS, positive VA or positive PS-VA type. The media have an improved long-term stability against UV radiation and elevated temperatures.
    Type: Application
    Filed: April 11, 2023
    Publication date: August 7, 2025
    Applicant: MERCK PATENT GmbH
    Inventors: Harald HIRSCHMANN, Sabine SCHOEN, Philipp WUCHER
  • Patent number: 12377056
    Abstract: The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: August 5, 2025
    Assignee: MERCK SERONO SA
    Inventors: H. James Brentzel, Jr., Maria Lopez-Bresnahan, Nazih Ammoury
  • Patent number: 12378273
    Abstract: The disclosed and claimed subject matter provides precursors having at least one tethered cyclopentadienyl ligand (“Cp ligand”), at least one amidinate ligand (“Ad ligand”) and a lanthanide and/or lanthanide-like transition metal (“M”) of the general formulae (i) (Cp ligand)2-M-(Ad ligand) or (ii) (Cp ligand)-M-(Ad ligand)2.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: August 5, 2025
    Assignees: Merck Patent GmbH, Versum Materials US, LLC
    Inventors: Christoph Wetzel, Holger Heil, Michal Krompiec, Lars Lietzau, David Bruge, Ming Fang, Sergei V. Ivanov
  • Publication number: 20250243491
    Abstract: Disclosed herein are short interfering RNA (siRNA) molecules that downregulate expression of PNPLA3 or variants thereof. The siRNA molecules comprise modified nucleotides and uses thereof. The siRNA molecules may be double stranded and comprise modified nucleotides, such as 2?-O-methyl nucleotides and 2?-fluoro nucleotides, and ligands.
    Type: Application
    Filed: September 1, 2022
    Publication date: July 31, 2025
    Applicants: Aligos Therapeutics, Inc., Merck Sharp & Dohme LLC
    Inventors: Leonid BEIGELMAN, Xuan LUONG, Saul MARTINEZ MONTERO, Aneerban BHATTACHARYA, Jerome DEVAL
  • Patent number: 12365838
    Abstract: A method for preparing a switching element which is operable in and electrically switchable between an optically clear state and a scattering state, wherein one or more polymerisable mesogenic compounds provided in a layer containing a liquid-crystalline medium which comprises one or more mesogenic compounds, one or more chiral compounds and the one or more polymerisable mesogenic compounds are subjected to polymerisation in the presence of a direct current (DC) electric field in the layer. Also, a switching element obtained or respectively obtainable by carrying out the method and to the use of the switching element in a window.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: July 22, 2025
    Assignee: Merck Patent GmbH
    Inventors: Roel van Raak, Paul Verbunt
  • Patent number: 12366562
    Abstract: A method is provided for preparing a sample of a specimen to be analysed from a thin-layer plate in thin-layer chromatography. The sample is removed from a surface of the thin-layer plate by means of a blade disposed at a receiving opening of a cannula and fed through the cannula to a specimen chamber connected to the cannula. A reduced pressure can be generated in the specimen chamber to suck the sample removed from the thin-layer plate by means of the cannula through the receiving opening into and through the cannula and into the specimen chamber. After removal and feed of the sample, the specimen chamber can be filled with a solvent to dissolve the sample.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: July 22, 2025
    Assignee: Merck Patent GmbH
    Inventors: Sarah Heub, Aurele Horisberger, Younouss Faye, Jean-Baptiste Orhan, Olivier Marti
  • Publication number: 20250230185
    Abstract: Provided herein are methods of separating host cell lipases from a production protein in chromatographic processes and methods of improving polysorbate-80 stability in a production protein formulation by separating host cell lipases from the production protein using chromatographic processes.
    Type: Application
    Filed: January 16, 2025
    Publication date: July 17, 2025
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Rebecca A. Chmielowski, Francis K. Insaidoo, Justin B. Miller, David J. Roush, Darshini Shah, John P. Welsh
  • Publication number: 20250230359
    Abstract: The new media exhibit a ferroelectric nematic phase preferably at ambient temperature. They preferably comprise one or more compounds selected from the group of compounds of formulae IA, IB and IC, in which the variable groups have the meanings indicated in the text and in the claims. Use of the media for providing ferroelectric nematic materials and a method of operation of an electro-optical device are presented. The media may be useful for energy-saving displays and electrical appliances.
    Type: Application
    Filed: December 27, 2024
    Publication date: July 17, 2025
    Applicant: MERCK PATENT GMBH
    Inventors: Matthias BREMER, Atsutaka MANABE, Martin KRASKA
  • Publication number: 20250230882
    Abstract: The present application relates to a holder for a fluid connector fitting and to a fluid dispenser including the same.
    Type: Application
    Filed: October 10, 2022
    Publication date: July 17, 2025
    Applicant: Merck Patent GmbH
    Inventor: Stephane OLIVIER
  • Publication number: 20250230360
    Abstract: Liquid-crystalline (LC) media having positive dielectric anisotropy and liquid-crystal displays (LCDs) containing these media, especially displays addressed by an active matrix and in particular energy efficient LC displays of the TN, PSTN, STN, TN-TFT, OCB, IPS, PS-IPS, FFS, HB-FFS, XB-FFS, PS-FFS, SA-HB-FFS, SA-XB-FFS, polymer stabilised SA-HB-FFS, polymer stabilised SA-XB-FFS, positive VA or positive PS-VA type. The media have an improved long-term stability against UV radiation and elevated temperatures.
    Type: Application
    Filed: April 11, 2023
    Publication date: July 17, 2025
    Applicant: MERCK PATENT GMBH
    Inventors: Harald HIRSCHMANN, Sabine SCHOEN, Philipp WUCHER
  • Patent number: 12359128
    Abstract: Heteroaromatic isothiocyanates of formula N wherein RN, AN1, AN2, ZN1, ZN2, W, X1, X2, and n are as defined herein can be used in liquid crystalline media. Liquid-crystalline media comprising one or more compounds of formula N are suitable for use in high-frequency components, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, tunable filters, tunable metamaterial structures, and electronic beam steering antennas, e.g., phased array antennas.
    Type: Grant
    Filed: December 14, 2021
    Date of Patent: July 15, 2025
    Assignee: MERCK PATENT GMBH
    Inventors: Constanze Brocke, Dagmar Klass, Carsten Fritsch, Amir Hossain Parham
  • Patent number: 12359164
    Abstract: The present invention relates to a process for manufacturing dry powder cell culture media. The preparation and usage of mixed particles generated by co-lyophilisation leads to cell culture media with improved solubility without changing the chemical composition.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: July 15, 2025
    Assignee: Merck Patent GmbH
    Inventors: Joerg Von Hagen, Nikolai Stankiewicz, Anke Simon
  • Patent number: 12360453
    Abstract: A resist composition which has as components a phenolic resin component, a photoactive 2,1,5-diazonaphthoquinonesulfonate component (PAC), a solvent component and that does not contain a photo acid generator (PAG). The PAC is a free PAC, a coupled PAC (PACb) or a combination thereof that includes a substituted or unsubstituted 2,1,5-DNQ material or compound onto which a substituted or unsubstituted 2,1,5-DNQ material is appended that, when UV exposed, do not form sulfonic acid. The phenolic resin component is a Novolak derivative in which some or all the free hydroxy groups are protected with an acid cleavable acetal moiety which can include a PACb moiety. A method whereby this composition is used in either thick or thin film photoresist device manufacturing methodologies.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: July 15, 2025
    Assignee: Merck Patent GmbH
    Inventors: Takanori Kudo, Hung-Yang Chen
  • Publication number: 20250223259
    Abstract: The present invention provides a compound of Formula I wherein A, M, R1, R2, R3a, R3b, and subscripts m and n are as described herein and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for the treatment, inhibition, or amelioration of one or more disease states that could benefit from inhibition of a coronavirus, including SARS-CoV, MERS-CoV and SARS-CoV-2. The compounds of this invention could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs useful for the treatment of coronavirus infection. The invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which comprise compounds of Formula I and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: January 5, 2023
    Publication date: July 10, 2025
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Brian T. Campbell, Wonsuk Chang, Timothy J. Hartingh, Danielle M. Hurzy, Michael J. Kelly, III, Franca-Maria Klingler, Mark E. Layton, John A. McCauley, Christopher Charles Nawrat, Craig A. Parish, James J. Perkins, Anthony J. Roecker, Manuel de Lera Ruiz, John D. Schreier, Valerie W. Shurtleff, Jing Su, Quang T. Truong
  • Publication number: 20250223496
    Abstract: A liquid-crystal (LC) medium or LC material based on a mixture of polar compounds, its use for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the vertically aligned mode and/or the fringe-field switching mode, an LC display of the vertically aligned mode and/or the fringe-field switching mode comprising the LC medium, especially an energy-saving LC display, and a process of manufacturing the LC display.
    Type: Application
    Filed: January 3, 2025
    Publication date: July 10, 2025
    Applicant: MERCK PATENT GmbH
    Inventors: Harald HIRSCHMANN, Sabine SCHOEN
  • Publication number: 20250223290
    Abstract: Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.
    Type: Application
    Filed: December 12, 2024
    Publication date: July 10, 2025
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Zachary G. Brill, Donna A.A.W. Hayes, Tom M. Lam, Kyle S. McClymont, Bryan S. Matsuura, Rohan Rajiv Merchant, Anilkumar G. Nair, Ning Qi
  • Patent number: 12351570
    Abstract: The present invention relates to disubstituted alkyne derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: July 8, 2025
    Assignee: MERCK PATENT GMBH
    Inventors: Timo Heinrich, Carl Petersson, Mireille Krier, Andrzej Gondela, Michal Mikolaj Galezowski, Charles-Henry Robert Yves Fabritius, Mateusz Oktawian Nowak, Marcin Krol
  • Patent number: 12350270
    Abstract: Methods of treating malaria comprising administration of compounds of Formula (I?) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: July 8, 2025
    Assignees: MSD R&D (China) Co. Ltd., The Walter and Eliza Hall Institute of Medical Research, Merck Sharp & Dohme LLC
    Inventors: John A. McCauley, Alan F. Cowman, Manuel de Lera Ruiz, Paola Favuzza, Zhuyan Guo, Bin Hu, Michael J. Kelly, III, Zhiyu Lei, David B. Olsen, Brad Sleebs, Jennifer K. Thompson, Tony Triglia, Dongmei Zhan, Cailing Zhang, Lianyun Zhao
  • Patent number: 12351630
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: July 8, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
  • Patent number: 12351594
    Abstract: The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: July 8, 2025
    Assignee: Merck Patent GmbH
    Inventors: Ilona Stengel, Aaron Lackner, Lara-Isabel Rodriguez, Charlotte Walter, Amel Mekic